Insider trade

Director sold ~$24K of UTHR shares in the open market

Traded Mar 17, 2026 · Filed Mar 18, 2026

Why it stands out

A United Therapeutics director sold $24K of United Therapeutics shares. The filing says it was made under a pre-arranged trading plan.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Director<$25KPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$24,008

Shares × reported transaction price

Timing vs results

20 days after results of Feb 25, 2026, 50 days before results of May 6, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	+2.1%	−0.7%	+2.8%
30 days	+10.9%	+7.4%	+3.6%
90 days	+3.4%	+13.4%	−10.1%
180 days	−5.2%	+15.0%	−20.3%

Past results only. Not a forecast.

This sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on September 11, 2025.

Automatic saleFiled 6mo ago

Filed 6mo ago

Traded Apr 14 · filed 3 days later

Derivative exercise or conversion — not an open-market buy.

Scheduled in advanceFiled 6mo ago